Back to results
US 2022/0017596 A1Published application
Multimeric t-cell modulatory polypeptides and methods of use thereof
AssigneeCue Biopharma, Inc.
InventorsSaso Cemerski, Anish Suri
Life of this patent
Estimating the term…
Abstract
The present disclosure provides T-cell modulatory multimeric polypeptides that comprise an immunomodulatory polypeptide, an epitope-presenting peptide, and class I MHC polypeptides. A T-cell modulatory multimeric polypeptide is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.
Claims50
A T-cell modulatory multimeric polypeptide comprising:
- at least one heterodimer comprising:
- a) a first polypeptide comprising:
- i) a peptide epitope, wherein the peptide epitope is a peptide having a length of at least 4 amino acids;
- and
- ii) first major histocompatibility complex (MHC) polypeptide;
- b) a second polypeptide comprising a second MHC polypeptide;
- c) at least one immunomodulatory polypeptide, wherein the first and/or the second polypeptide comprises the at least one immunomodulatory polypeptide;
- d) an immunoglobulin (Ig) Fc polypeptide or a non-Ig scaffold, wherein the first and/or the second polypeptide comprises the Ig Fc polypeptide or the non-Ig scaffold;
- and
- e) a tumor-targeting polypeptide, wherein the first and/or the second polypeptide comprises the tumor-targeting polypeptide.
7 more elements
Dependencies are inferred from the claim text.